^
    Back
    Association details:
    Biomarker:IL10-L
    Cancer:Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2023
    Title:

    3249 / 22 - Circulating cytokine associations with clinical outcomes in melanoma patients treated with checkpoint inhibitors

    Published date:
    03/15/2023
    Excerpt:
    Pre-treatment, patients with durable clinical benefit (DCB) had higher IL23, lower CXCL6, and lower IL10 levels….Baseline measurement of cytokines IL23, CXCL6, and IL10 can predict metastatic melanoma patients’ response to ipi/nivo combination treatment.